secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADC Therapeutics SA (ADCT)
CIK:        0001771910
Form:       8-K
Filed at:   2024-03-13T23:59:59+00:00
Accession:  0001628280-24-010785
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ADC Therapeutics reports Q4'23 ZYNLONTA sales $16.6M, net loss $85M; cash runway into Q4'25
--------------------------------------------------------------------------------

- ZYNLONTA net sales $16.6M in Q4'23 (+17% QoQ, -16% YoY); FY'23 $69.1M (-8% YoY).
- Net loss $85M in Q4'23 ($1.03/share) vs $23.3M loss in Q4'22; FY'23 net loss $240.1M ($2.94/share).
- Cash $278.6M, expected runway into Q4'25; operating expenses decreased 21% YoY.
- LOTIS-5 may need additional patients beyond 350; enrollment still expected to complete in 2024.
- ADCT-601 pancreatic cancer screening initiated; LOTIS-7 dose escalation cleared at 150 µg/kg.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1771910/000162828024010785/0001628280-24-010785-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1771910/000162828024010785/adc-20240313.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-010785

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer